ISTO Technologies Assumes Full Control of DeNovo ET Cartilage Repair Technology Program
Collaboration Agreement with Zimmer Holdings, Inc. Ended
ISTO to Proceed Independently with Phase III Clinical Trial
ISTO Technologies, Inc., a privately-held orthobiologics company, announced today that it is participating in the 8th Annual Canaccord Genuity Musculoskeletal Conference to be held on Tuesday, March 19, 2013.
Orthopedic Design & Technology Online Exclusive - ISTO's NuQu Technology: The "Magic Bullet" for Cartilage Regeneration? The company's CEO spoke with ODT about the future of the firm's technology and more.
ISTO Technologies, Inc. announced the publication of a scientific paper in a leading peer-reviewed neurosurgery journal, the Journal of Neurosurgery: Spine. The manuscript, entitled "Prospective study of disc repair with allogeneic chondrocytes" by Domagoj Coric, M.D., Kenneth Pettine, M.D., Andrew Sumich, M.D. and Margaret O. Boltes, R.N., is currently available on-line at www.thejns.org as a "Publish Before Print" article and will soon be available in an upcoming publication.
ISTO Technologies, Inc. announced today that it is initiating a Phase II trial to further evaluate the efficacy and safety of its NuQu® cell-based therapy for the treatment of pain and disability associated with degenerated spinal discs.
ISTO Technologies, Inc. announced today that Mitchell Seyedin, Ph. D., President and Chief Executive Officer, will participate as a panelist and presenter in the Noble Financial Capital Markets BIOX Life Sciences Exposition in Stamford, CT.
ISTO Technologies Inc. announced the addition of a medical technology industry veteran, John Hart, to its senior management team. Mr. Hart joined the Company as its Chief Operating Officer as of July 16, 2012.
ISTO Technologies, Inc., a leading orthobiologics company focused on developing breakthrough products to regenerate and restore function to damaged cartilage and bone, announced today that the United States Patent and Trademark Office (USPTO) has issued a fundamental patent for the technology on which the company's InQu® Bone Graft Extender & Substitute is based. U.S-patent No. 8,192,759, "Matrix Made of Polyester Polymers Entangled with Hyaluronic Polymers Useful for Supporting Tissue Repair", covers the unique biosynthetic structure of ISTO's product.
Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a global leader in musculoskeletal health, and ISTO Technologies, Inc., an orthobiologics company focused
on developing breakthrough products to regenerate and restore function to damaged cartilage and bone, today announced a Phase III clinical study to evaluate DeNovo® ET Engineered Tissue Graft, an engineered cartilage implant intended to repair cartilage defects in the knee. DeNovo ET Graft is being developed under a collaborative relationship between ISTO and Zimmer.
ISTO Technologies, Inc., today announced that Scott Gill, Chief Financial Officer will be participating in a panel session at the Regenerative Medicine Insight Track at the Biotech Showcase being held January 9-11, 2012 in San Francisco.
St. Louis, MO, October 13, 2011 - ISTO Technologies, Inc., an orthobiologics company developing innovative cartilage and bone products for spinal therapy and sports medicine indications, today announced that it has received the Conformité Européenne (CE) Mark approval for its InQu® product line. InQu is a unique bone graft substitute and extender currently sold through a network of independent distributors in the United States. Receipt of the CE Mark enables ISTO to initiate a commercial launch of the product in Europe.
ISTO Technologies, Inc., a privately-held orthobiologics company, announced today that Mitchell Seyedin, Ph. D., President and Chief Executive Officer, is scheduled to present at the 22nd Annual Piper Jaffray Health Care Conference in New York, NY.
ISTO Technologies, Inc. announced today that it will participate in the BMO Capital Markets' 10th Annual Focus on Healthcare Conference to be held at the Sheraton New York Hotel & Towers in New York, NY on August 5,1 2010. Mitchell Seyedin, Ph. D., President and CEO, is scheduled to present a 30-minute overview of the company at 3:00 p.m. Eastern Time on Thursday, August 5th. The conference will feature presentations from over 90 public and private healthcare companies in the biotechnology, medical devices healthcare services and pharmaceutical areas.
ISTO Technologies, Inc. announced today that it has received notification from the (FDA) allowing the company to proceed with a Phase I clinical study for NuQu™, an injectable therapy intended to regenerate the spinal disc nucleus.
Based on its recent analysis of the bone healing market, Frost & Sullivan recognizes ISTO Technologies, Inc. with the 2008 North American Frost & Sullivan Award for Product Innovation for its novel InQu® Bone Graft Extender and Substitute scaffold.